Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies

Cytokines and Molecular Therapy

Volumn 2, Issue 2, 1996, Pages 239-242

  Demeter, Judith ^a,b   Messer, Gerald ^a   Rämisch, Stephanie ^b   Mee, John B ^b   Di Giovine, Francesco S ^c   Schmid, Mathias ^c   Herrmann, Friedhelm ^d   Porzsolt, Franz ^d  

^a UNIVERSITY OF ULM   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FREQUENCY; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; HUMAN CELL; INTRON; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; VARIABLE NUMBER OF TANDEM REPEAT;

ALLELES; GENE FREQUENCY; GENOTYPE; HEMATOLOGIC NEOPLASMS; HODGKIN DISEASE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LEUKEMIA; LYMPHOMA; MINISATELLITE REPEATS; MULTIPLE MYELOMA; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, GENETIC; REFERENCE VALUES; SIALOGLYCOPROTEINS;

EID: 0030484503     PISSN: 13556568     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Duff GW, Molecular genetics of cytokines: cytokines in chronic inflammatory disease. In: The Cytokine Handbook (ed A Thompson) 21-30. Academic Press, London, 1994.
2. Kurzrock R, Wetzler M, Estrov Z, Talpaz M, Interleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth factor regulatory molecules in leukemias. Cytokines Mol Tlier (1995) 1: 177-84.
3. Nicklin MJH, Weith A, Duff GW, A physical map of the region encompassing the human interleuklin1 alpha, interleukin-1 beta and interleukin-1 receptor antagonist genes. Genoniics (1994) 19: 382-4.
4. Dinarello CA, Biologic basis for interleukin-1 in disease. Blood (1996) 87: 2095-147.
5. di Giovine FS, Duff GW, Interleukin 1: the first interleukin. Immunol Today (1990) 11: 13-20.
6. Engenvall P, Andersson B, Björkholm M, Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia. Br J Haematol (1995) 91: 838-45.
7. Cozzolino R, Rubartelli A, Aldinucci D et al, Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. Proc Natl Acad Sci USA (1989) 86: 2369-72.
8. Aguilar-Santelises M, Amador JF, Mellstedt H, Jondal M, Low IL-1 beta production in leukemic cells from progressive B cell chronic lymphocytic leukemia (BCLL). Lenk Res (1989) 13: 937-42.
9. Cozzolino F, Torcia M, Aldinucci D et al, Production of IL-1 by bone marrow myeloma cells. Blood (1989) 74: 380-7.
10. Kawano M, Yamamoto I, Iwato K et al, Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood (1989) 73: 1646-9.
11. Barak V, Nisman B, Dann EJ et al, Serum interleukin1 beta levels as a marker in hairy cell leukemia: correlation with disease status and sIL-2R levels. Lenk Lymphoma (1994) 14: 33-9.
12. Hsu SM, Krupen K, Lachmann LB, Heterogeneity of interleukin-1 production in cultured Reed-Sternberg cell lines HDLM-1, HDLM-ld and KM-H2. AmJ Pathol (1989) 135:33-8.
13. Gruss HJ, Dölken G, Brach MA et al, High concentration of the interleukin-1 receptor antagonist in serum of patients with Hodgkin's disease. Lancet (1992) 340: 968.
14. Bailly S, di Giovine FS, Blakemore AIF, Duff GW, Genetic polymorphism of human interleukin-1 a. Eur J Iminunol (1993) 23: 1240-5.
15. Pociot F, Molvig J, Wogensen L et al, A Taql polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur3 Clin Invest (1992) 22: 396-402.
16. McDbwell TL, Symons JA, Ploski R et al, A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 a polymorphism. Arthritis Rheum (1995) 38: 221-8.
17. Tarlow JA, Blakemore AIF, Lennard A et al, Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86bp tandem repeat. Hum Genet (1993) 91: 403-4.
18. Blakemore AIF, Tarlow JK, Cork MJ et al, Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum (1994) 37: 1380-5.
19. Blakemore AIF, Watson RF, Weetman AP, Duff Gw, Association of Graves' disease with an allele of the interleukin-1 receptor antagonist gene. J Clin Endocnnol Metab (1995) 80: 111-15.
20. Blakemore AIF, Cox A, Gonzalez AM et al, Interleukin-1 receptor antagonist allele (IL1RN2) associated with nephropathy in diabetes mellitus. Hum Genet (1996) 97: 369-74.
21. Clay FE, Cork MJ, Tarlow JK et al, Interleukin-1 receptor antagonist gene polymorphism association with lichen sclerosus. Hum Genet (1994) 94: 407-10.
22. Mansfield JC, Holden H, Tarlow JK et al, Novel genetic association between ulcerative colitis and the anti-inflammatory cytokiné interleukin-1 receptor antagonist. Gastroenterology (1994) 106: 637-42.
23. Tarlow JK, Clay FE, Cork MJ et al, Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. J Invest Dennatol (1994) 103: 387-90.
24. Danis VA, Millington M, Hyland VJ, Grennan D, Cytokine production by normal human monocytes: intersubject variation and relationship to an IL-1 receptor antagonist (IL-IRa) gene polymorphism. Clin Exp Immunol (1995) 99: 303-10.
25. Zsebo KM, Wypych J, Yuschenkoff VN et al, Effects of hematopoetin-1 and interleukin-1 activities on early hematopoietic cells of the bone marrow. Blood (1988) 71: 962-8.
26. Cogswell JP, Godlevski NM, Wisely GB et al, NF-KB regulates IL-I transcription through a consensus NF-KB binding site and a nonconsensus CRE-like site. J Immunol ( 1994) 163: 712-19.
27. Carter A, Silvian-Draxler I, Tatarsky I, Effect of interleukin-1, tumor necrosis factor-a and interferona on the blast cells of acute myeloblastic leukemia. Am J Hematol (1992) 40: 245-51.
28. Oster W, Cicco NA, Klein H et al, Participation of the cytokines TNF-a, IL-6 and IL-I secreted by AML cells in autocrine and paracrine leukemia growth control. J Clin Invest (1989) 84: 451-7.
29. Estrov Z, Kurzrock R, Estey E et al, Inhibition of acute myelogenous leukemia blast cell proliferation by IL-1 receptor antagonist and soluble IL-1 receptors. Blood (1989) 79: 1938-45.
30. Estrov Z, Kurzrock R, Talpaz M, Role of interleukin1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. Lenk Lymphoma (1993) 10: 407-18.
31. 243-250 Soluble tumor necrosis factor (sTNF) receptors: A possible prognostic marker for bone marrow transplantation-related complications Reuven Or, 1 Alexander Kalinkovich, 2 Amnon Nagler, 1 Ziva Weisman, 2 Elizabeth Naparstek, 1 Lola Weiss 1 and Talia Hahn 3 1 Department of Bone Marrow Transplantation and Cancer Immunobiology Research Laboratory, Hadassah University Hospital, Jerusalem, Israel; 2R Ben-Ari Institute of Clinical Immunology and 3Pediatric Research Institute, Kaplan Hospital, Rehovot, Israel Reuven Or, MD, Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem 91120, Israel (Fax +972 2 6422731). Involvement of tumor necrosis factor (TNF) in bone marrow transplantation (BMT)-associated complications has been documented. Biological response to TNF requires interaction with specific cell membrane receptors. Extracellular domains of these receptors are released into body fluids as soluble molecules, and participate in the bioactivity of TNF. Serum levels of p55 and p75 soluble tumor necrosis factor receptors (sTNFR) were determined in 34 patients with different diseases who underwent BMT. Sequential studies initiated 10 days before BMT and continued up to 110 days post-transplantation showed that p55 and p75 sTNFR levels were elevated significantly in patients who subsequently developed major transplantrelated complications (TRC). Moreover, both sTNFR levels were increased 2- to 3-fold over control values during postBMT febrile periods in those patients who at a later stage suffered major TRC. These results indicate that the serum level of sTNFR may be used as a prognostic marker for major TRC in BMT. Key words: Soluble tumor necrosis factor receptors; bone marrow transplantation © 1996 Martin Dunitz Ltd
32. Vogelsang GB, Acute and chronic graft-versus-host disease. Curr Opin Oncol (1993) 5: 276-81.
33. Antin JH, Ferrara JL, Cytokine dysregulation and acute greaft-versus-host disease. Blood (1992) 80: 2964-8.
34. Jadus MR, Wepsic H, The role of cytokines in graftversus-host reactions and disease. Bone Marroîo Transplant (1992) 10: 1-14.
35. Ferara JL, Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immnnol (1993) 5: 794-9.
36. Piguet PF, Grau GE, Allet B, Vassalli P, Tumor necrosis factor/cachectin is an effector of skin and gur lesions of rhe acute phase of graft-vs-host disease. J ExpMed(l9S7) 166: 1280-9.
37. Imagawa DK, Millis JM, Olthoff KN et al, The role of tumor necrosis factor in allograft rejection. I. Evidence that elevated levels of tumor necrosis factoralpha predict rejection following orthotopic liver transplantation. Transplantation (1990) 50: 219-25.
38. Tiberghien P, Racadot E, Lioure B et al, Soluble CDS IL-2 receptor, and tumor necrosis factor-alpha levels in steroid resistant acute graft-versus-host disease: Relation with subsequent response to anti-IL2 receptor monoclonal antibody treatment. Transplantation (1991) 52: 475-80.
39. Nestel FP, Price KS, Seemayer TA, Lapp WS, Macrophage priming and lipopolysaccharidetriggered release of tumor necrosis factor a during graft-versus-host disease. J Exp Aied (1992) 175: 405-13.
40. Meliconi R, Uguccioni M, Lalli et al, Increased serum concentrations of tumour necrosis factor in thalassemia: effect of bone marrow transplantation. J Clin Pathol (1992) 45: 61-5.
41. Robinet E, Ibrahim A, Truneh A et al, Serum levels and receptor expression of tumor necrosis factoralpha following human allogeneic and autologous bone marrow transplantation. Transplantation (1992) 53: 574-9.
42. Shalaby MR, Fendly B, Sheehan KG et al, Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. Transplantation (1989) 47: 1057-61.
43. Imagawa DK, Millis JM, Seu P et al, The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. Transplantation (1991) 51: 57-62.
44. Scheringa M, de Bruin RW, Jeekel H, Marquet RL, Anti-tumor necrosis factor alpha serum prolongs heart allograft survival in rats. Transplant Proc (1991) 23: 547-8.
45. Hervé P, Flesch M, Tiberghien P et al, Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood (1992) 79: 3362-8.
46. Holler E, Kolb HJ, Moller A et al, Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood (1990) 75: 1011-16.
47. Holler E, Kolb HJ, Hintermeier-Knabe R et al, Role of tumor necrosis factor alpha in acute graft-versushost disease and complications following allogeneic bone marrow transplantation. Transplant Proc (1993) 25: 1234-6.
48. Loetscher H, Steinmetz W, Lesslauer W, Tumor necrosis factor: receptors and inhibitors. Cancer Cells (1991) 3: 221-6.
49. Warzocha K, Bienvenu J, Coiffier B, Salles G, Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system. Eur Cytokim Netw (1994) 5: 83-96.
50. Olsson I, Gatanaga T, Gullberg U et al, Tumor necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw (1993) 4: 169-80.
51. Miles DW, Aderka D, Engelmann H et al, Induction of soluble tumour necrosis factor receptors during treatment with interleukin 2. Br J Cancer (1992) 66: 1195-9.
52. Van Zee KJ, Kohno T, Fischer E et al, Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA (1992) 89: 4845-9.
53. Spinas GA, Keller U, Brockhaus M, Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest (1992) 90: 533-6.
54. Girardin E, Roux-Lombard P, Grau GE et al, Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia: theJ5 Study Group. Immunology (1992) 76: 20-3.
55. Heilig B, Wermann M, Gallati H et al, Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. J Clin Invest (1992) 70: 22-7.
56. Cope AP, Aderka D, Doherty M et al, Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluids of patients with rheumatic diseases. Arthritis Rlieum (1992) 35: 1160-9.
57. Parsons PE, Moore FA, Moore EE et al, Studies on the role of tumor necrosis factor in adult respiratory distress syndrome. Am Rev Respir Dis (1992) 146: 694-700.
58. Hintermeier-Knabe R, Brockhaus M, Holler E et al, Sequential release of tumor necrosis factor alpha and tumor necrosis factor receptors in complications of human bone marrow transplantation. In: Cytokims in hemopoiesis, oncology and AIDS II (ed M Freund, H Link, RE Schmidt, K Weite) 443-8. Springer-Verlag, Berlin, 1992.
59. Chasty RC, Lamb WR, Gallati H et al, Serum cytokine levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant (1993) 12: 331-6.
60. Racadot E, Cahn JY, Brion A et al, Cytokines, cytokine receptors and adhesion molecules after allogeneic bone marrow transplantation. In: Challenges of modem medicine (ed S Romagnani, G Del Prête, AK Abbas) 293-7. Serono, Florence, 1994.
61. Kalinkovich A, Livshits G, Engelmann H et al, Soluble tumour necrosis factor receptors (sTNF-R) and HIV infection: correlation to CD8+ lymphocytes. Clin Exp Immwwl (1993) 93: 350-5.
62. Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev (1985) 88: 215-38.
63. Hahn T, Schattner A, Handzel ZT et al, Possible role of natural cytotoxic activity in the pathogenesis of AIDS. Clin Immunol Immitnopathol (1989) 50: 53-61.
64. Vassali P, The pathophysiology of tumor necrosis factors. Ann Rev Immunol (1992) 10: 411-52.
65. Pigeut PP, TNF and alloreactions: involvement of TNF in the effector phase of graft-versus-host and host-versus-graft reactions. In: Tumor necrosis factor: the molecules and their emerging role in medicine (ed B Beutler) 341-54. Raven Press, New York, 1992.
66. Or R, Matzner Y, Konijn AM, Serum ferritin in patients undergoing bone marrow transplantation. Cancer (1987) 60: 1127-31.
67. Symington FW, Pepe MS, Chen AB, Deliganis A, Serum tumor necrosis factor alpha association with acute graft-versus-host disease in humans. Transplantation (1990) 50: 518-21.
68. Engelberts I, Stephens S, Franco! GJ et al, Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet (1991) 338: 515-6 (letter).
69. Dinarello CA, Cannon JG, Cytokine measurements in septic shock. Ann Intern Med (1993) 119: 853-4 (editorial).
70. Kapadia S, Torre-Amione G, Mann DL, Pitfalls in measuring cytokines. Ann Intern Med (1994) 121: 149-50.
71. Lesslauer W, Tabuchi H, Gentz R et al, Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharideinduced lethality. Etir J Imiminol (1991) 21: 2883-6.
72. Engelberts I, Moller A, Leeuwenberg JPM et al, Administration of tumor necrosis factor a (TNFa) inhibitors after exposure to TNFa prevents development of the maximal biological effect: an argument for clinical treatment with TNFa inhibitors. J Surg tfes (1992) 53:510-4.
73. Haak-Frendscho M, Marsters SA, Mordend J et al, Inhibition of TNF by a TNF receptor immunoadhesin: comparison to an anti-TNF monoclonal antibody. J Immwiol ( 1994) 152: 1347-53.
74. Mohler KM, Torrance DS, Smith ÇA et al, Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. JImmunol (1993) 151: 1548-61.
75. Aderka D, Engelmann H, Maor Y et al, Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors, jf Exp Med (1992) 175: 323-9.